4D Molecular Therapeutics Files 8-K
Ticker: FDMT · Form: 8-K · Filed: Jun 7, 2024 · CIK: 1650648
| Field | Detail |
|---|---|
| Company | 4d Molecular Therapeutics, INC. (FDMT) |
| Form Type | 8-K |
| Filed Date | Jun 7, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $250.0 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, financial-statements, filing
TL;DR
4D Molecular Therapeutics filed an 8-K on June 7, 2024, likely for a material agreement or financial update.
AI Summary
On June 7, 2024, 4D Molecular Therapeutics, Inc. filed an 8-K report. The filing indicates the company entered into a material definitive agreement and also includes financial statements and exhibits. Specific details of the agreement and financial figures were not provided in the initial filing header.
Why It Matters
This filing signals a significant event for 4D Molecular Therapeutics, potentially involving a new contract or financial update that could impact investors.
Risk Assessment
Risk Level: medium — An 8-K filing often contains material information that can significantly impact a company's stock price, but the lack of specific details in the header makes the immediate risk level uncertain.
Key Players & Entities
- 4D Molecular Therapeutics, Inc. (company) — Registrant
- June 7, 2024 (date) — Date of Report
FAQ
What is the nature of the material definitive agreement entered into by 4D Molecular Therapeutics?
The provided filing header does not specify the details of the material definitive agreement.
What financial statements and exhibits are included in this 8-K filing?
The filing header indicates that financial statements and exhibits are included, but their specific content is not detailed.
When was this 8-K report filed?
The report was filed on June 7, 2024.
What is the principal executive office address for 4D Molecular Therapeutics?
The address is 5858 Horton Street #455, Emeryville, California, 94608.
What is the SIC code for 4D Molecular Therapeutics?
The Standard Industrial Classification (SIC) code is 2836, for Biological Products (No Diagnostic Substances).
Filing Stats: 909 words · 4 min read · ~3 pages · Grade level 12 · Accepted 2024-06-07 17:07:30
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share FDMT Nasdaq Glo
- $250.0 million — he offering, the Company may sell up to $250.0 million of common stock through the Agent. Sale
Filing Documents
- d835355d8k.htm (8-K) — 29KB
- d835355dex11.htm (EX-1.1) — 185KB
- d835355dex51.htm (EX-5.1) — 13KB
- g835355g0607134927174.jpg (GRAPHIC) — 2KB
- g835355g62s37.jpg (GRAPHIC) — 4KB
- 0001193125-24-157521.txt ( ) — 417KB
- fdmt-20240607.xsd (EX-101.SCH) — 3KB
- fdmt-20240607_lab.xml (EX-101.LAB) — 18KB
- fdmt-20240607_pre.xml (EX-101.PRE) — 11KB
- d835355d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 1.1 Sales Agreement, dated June 7, 2024, by and between the Company and Leerink Partners LLC 5.1 Opinion of Latham & Watkins LLP 23.1 Consent of Latham & Watkins LLP (included in Exhibit 5.1) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 4D MOLECULAR THERAPEUTICS, INC. Date: June 7, 2024 By: /s/ Uneek Mehra Uneek Mehra Chief Financial and Business Officer